Zevia PBC Reports Significant Profitability Improvement and Positive 2026 Outlook
ZVIA is trading near its 52-week low of $1.485 (2.8% below the low).
Summary
Zevia PBC reported significantly improved profitability for full-year 2025 and provided positive guidance for 2026, projecting sales growth and a path to positive Adjusted EBITDA, alongside a board leadership change.
Key Events · Earnings and Guidance · ZVIA
-
Improved Full Year 2025 Financials
Net sales increased 4.0% to $161.3 million. Net loss significantly improved to $11.2 million from $23.8 million in 2024, and Adjusted EBITDA loss narrowed substantially to $4.7 million from $15.2 million.
-
Positive 2026 Outlook
The company projects full-year 2026 net sales between $169 million and $173 million, and anticipates Adjusted EBITDA to range from a loss of $1.0 million to positive $0.5 million, signaling a path to profitability.
-
Board Leadership Transition
Andrew Ruben, the current Lead Independent Director, has been appointed Chair of the Board, replacing Padraic Spence, who will remain a board member.
Analysis · ZVIA · Manufacturing
Zevia PBC's latest earnings report signals a significant operational turnaround, with substantial improvements in full-year 2025 profitability metrics. The company reduced its net loss by over 50% and dramatically narrowed its Adjusted EBITDA loss, demonstrating effective cost management and strategic initiatives. The positive guidance for 2026, projecting continued sales growth and a move towards Adjusted EBITDA breakeven or positive, provides a crucial outlook for investors, especially as the stock trades near its 52-week lows. This financial improvement could help counter recent negative sentiment from institutional insider selling. The appointment of an experienced Lead Independent Director, Andrew Ruben, as the new Board Chair also suggests a focus on stable leadership during this pivotal period.
At the time of this filing, ZVIA was trading at $1.44 on NYSE in the Manufacturing sector, with a market capitalization of approximately $116.3M. The 52-week trading range was $1.49 to $3.66. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.